NCT04824092 2026-04-01
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
NCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT05429268 2025-12-10
firmMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05626322 2025-09-05
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
Phase 1/2 Terminated
NCT02763319 2025-07-17
B-MIND
Incyte Corporation
Phase 2/3 Completed
NCT04981795 2024-12-10
realMIND
Incyte Corporation
Recruiting
NCT04134936 2024-10-16
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
MorphoSys AG
Phase 1 Completed
NCT05328102 2024-04-30
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Xencor, Inc.
Phase 2 Terminated
NCT02399085 2023-10-23
L-MIND
MorphoSys AG
Phase 2 Completed
NCT04300803 2020-08-28
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
MorphoSys AG
Approved for marketing